Tivic Reports Q2 Financial Results, Advances TLR5 Agonist Program

• Tivic Health reported Q2 2025 financial results • Company advancing TLR5 agonist program and VNS clinical data • Shifted resources away from consumer healthtech • Planning to exit ClearUP business by end of 2025 • Diversified immunotherapeutics company • Unique approach to disease treatment • Addressing biochemical and bioelectronic systems

Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, has announced its financial results for the second quarter and six months ended June 30, 2025. The company reported revenue of $86,000 and $156,000 for the three and six months ended June 30, 2025, respectively, compared to $140,000 and $474,000 for the same periods in 2024. Gross profit for the six months ended June 30, 2025, was $104,000, compared to $197,000 in 2024, while operating expenses increased to $3.5 million from $3.0 million in 2024 [1].

Tivic CEO Jennifer Ernst highlighted the company's strategic transformation into biopharmaceuticals, stating, "We have established a strong foundation for Tivic’s strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body’s biochemical and bioelectronic systems." The company is shifting resources away from consumer healthtech and plans to exit the ClearUP business by the end of 2025 [2].

Significant advancements include securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS, extending the worldwide license of Entolimod™ to include neutropenia treatment, and entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. The company also completed all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device [1].

Tivic raised $1.4 million from the first and second tranche of a preferred equity purchase agreement, generating net proceeds of $547,000 from a $25 million equity line of credit. The company has no debt on its balance sheet and believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod™ [1].

Management will host a webcast/conference call on August 14, 2025, to discuss the company’s second quarter 2025 financial results and provide a business update [1].

References:
[1] https://www.marketscreener.com/news/tivic-reports-second-quarter-2025-financial-results-ce7c51d9dc80f222
[2] https://www.theglobeandmail.com/investing/markets/markets-news/Business%20Wire/34160236/tivic-reports-second-quarter-2025-financial-results/